phentolamine 0.75% · ophthalmic solution
Misc.
Approved uses
Reversal of pharmacologically induced mydriasis, age 12 and over
1 or 2 drops in each dilated eye after the examination or procedure is finished; if 2 drops are instilled, the second drop should be administered 5 minutes after the first drop
An alpha-1 blocker used to end the dilation rather than to produce it, which shortens the hours of glare after an exam
Contraindications
None.
Phentolamine ophthalmic solution 0.75%, 0.2 mL single-dose vials, 25 or 30 vials
Ryzumvi is a relatively non-selective alpha-1 and alpha-2 adrenergic antagonist. Physiological dilation of the pupil is primarily controlled by the radial iris dilator muscles surrounding the pupil; these muscles are activated by the alpha-1 adrenergic receptors. Phentolamine reversibly binds to these receptors on the iris dilator muscle, thereby reducing pupil diameter, with no effect on the ciliary muscle. Phentolamine directly antagonizes the mydriatic effect of an α-1 adrenergic agonist, and indirectly reverses mydriasis induced by muscarinic antagonist effects on the iris sphincter muscle.
Warnings & Precautions
- Uveitis: not recommended when active ocular inflammation (e.g., iritis) is present because adhesions (synechiae) may form between the iris and the lens.
- Contact lenses: remove them before instilling RYZUMVI and wait 10 minutes after dosing before reinserting them.
- Eye injury or contamination: avoid touching the vial tip to the eye or any other surface.
Common Side Effects
For presbyopia, the most common ocular adverse reactions were conjunctival hyperemia (21%) and instillation site irritation (16%). For pharmacologically-induced mydriasis, the most common ocular adverse reactions were instillation site discomfort including pain, stinging, and burning (16%) and conjunctival hyperemia (12%), and the only non-ocular adverse reaction in more than 5% of subjects was dysgeusia (6%).
Pregnancy: There are no available data with RYZUMVI administration in pregnant women to inform a drug-associated risk. Oral phentolamine in pregnant mice and rats during organogenesis caused skeletal immaturity and decreased growth in the offspring at doses at least 24-times the recommended clinical dose, and a lower rate of implantation in rats at least 60-times the recommended clinical dose; no malformations or embryofetal deaths were observed. RYZUMVI should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.
Lactation: There is no information regarding the presence of phentolamine in human milk, the effects on the breastfed infants, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for RYZUMVI and any potential adverse effects on the breastfed child.
Safety and effectiveness for pharmacologically-induced mydriasis have been established in pediatric patients aged 3 to 17 years, with no overall differences between pediatric and adult subjects. Presbyopia does not occur in the pediatric population.